Phospholipases A2 and platelet-activating-factor acetylhydrolase in patients with acute respiratory distress syndrome

Critical Care Medicine

Volumn 33, Issue 4, 2005, Pages 772-779

  Nakos, George ^a   Kitsiouli, Eirini ^b   Hatzidaki, Eleana ^b   Koulouras, Vassilios ^a   Touqui, Lhousseine ^c   Lekka, Marilena E ^b  

^a UNIVERSITY HOSPITAL OF IOANNINA   (Greece)

^b UNIVERSITY OF IOANNINA   (Greece)

^c INSTITUT PASTEUR   (France)

Author keywords

Acute lung injury; Acute respiratory distress syndrome; Fluorescence; Phospholipase A2; Platelet activating factor acetylhydrolase

Indexed keywords

1 ALKYL 2 ACETYLGLYCEROPHOSPHOCHOLINE ESTERASE; CALCIUM ION; LY 311727; ML 3176; PHOSPHOLIPASE A2; PHOSPHOLIPASE A2 INHIBITOR; UNCLASSIFIED DRUG; ACETYLCHOLINE; BIOLOGICAL MARKER; CALCIUM; PHOSPHOLIPASE A;

ADULT; ADULT RESPIRATORY DISTRESS SYNDROME; AGED; ARTICLE; ARTIFICIAL VENTILATION; BIOCHEMISTRY; CLINICAL ARTICLE; CONTROLLED STUDY; CORRELATION ANALYSIS; ENZYME ACTIVITY; ENZYME ASSAY; FEMALE; FIBEROPTIC BRONCHOSCOPY; FLUOROMETRY; HUMAN; HUMAN CELL; INTENSIVE CARE UNIT; LUNG LAVAGE; MALE; MORTALITY; OXYGEN TENSION; PRIORITY JOURNAL; PROSPECTIVE STUDY; PROTEIN FUNCTION; UNIVERSITY HOSPITAL; WESTERN BLOTTING; CHEMISTRY; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; ENZYMOLOGY; METABOLISM; MIDDLE AGED; STATISTICAL MODEL; SURVIVAL;

1-ALKYL-2-ACETYLGLYCEROPHOSPHOCHOLINE ESTERASE; ACETYLCHOLINE; BIOLOGICAL MARKERS; BLOTTING, WESTERN; BRONCHOALVEOLAR LAVAGE FLUID; CALCIUM; FEMALE; HUMANS; LOGISTIC MODELS; MALE; MIDDLE AGED; PHOSPHOLIPASES A; RESPIRATORY DISTRESS SYNDROME, ADULT; SURVIVAL ANALYSIS;

EID: 17044375549     PISSN: 00903493     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.CCM.0000158519.80090.74     Document Type: Article

References (48)

1. 2. Annu Rev Pharmacol Toxicol 1999; 39:175-189
2. 2: Mediators of inflammation, proliferation and apoptosis. Prog Lipid Res 2001; 40:167-197
3. Tjoelker LW, Wilder C, Eberhardt C, et al: Anti-inflammatory properties of a platelet-activating factor acetylhydrolase. Nature 1995; 374:549-553
4. 2 protein interaction. J Clin Invest 1998; 102:1152-1160
5. Furue S, Kuwabara K, Mikawa K, et al: Crucial role of group IIA phospholipase A(2) in oleic acid-induced acute lung injury in rabbits. Am J Respir Crit Care Med 1999; 160:1292-1302
6. 2 induced pathophysiology changes in guinea pig lung. Am J Pathol 1990; 136:1283-1291
7. 2 inhibitor in rabbit acute lung injury: Correlation with lung surfactant protection. Crit Care Med 2001; 29:719-727
8. 2 regulates critical inflammatory mediators of multiple organ failure. J Surg Res 1994; 56:199-205
9. Jehle R, Schlame M, Buttner C, et al: Platelet-activating factor (PAF)-acetylhydrolase and PAF-like compounds in the lung: Effects of hyperoxia. Biochim Biophys Acta 2001; 1532:60-66
10. Bernard GR, Artigas A, Brigham KL, et al: Definitions, mechanisms, relevant outcomes, and clinical trial coordination: The American-European Consensus Conference on ARDS. Am J Respir Crit Care Med 1994; 149:818-824
11. Knaus W, Draper E, Wagner D, et al: APACHE II: A severity of disease classification system. Crit Care Med 1985; 13:818-829
12. Nakos G, Kitsiouli E, Lekka ME: Bronchoalveolar lavage alterations in pulmonary embolism. Am J Respir Crit Care Med 1998; 155:945-950
13. Bradford M: A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem 1976; 72:248-254
14. Putman E, Creuwels LAJM, van Golde LMG, et al: Surface properties, morphology and protein composition of pulmonary surfactant subtypes. Biochem J 1996; 320:599-605
15. Bligh EG, Dyer WJ: A rapid method of total lipid extraction and purification. Can J Biochem Physiol 1959; 37:911-917
16. Bartlett GR: Phosphorus assay in column chromatography. J Biol Chem 1959; 234:466-468
17. 2 and PAF-acetylhydrolase in biological fluids using fluorescent substrates. J Lipid Res 1999; 40:2346-2356
18. 2 in animal models of acute lung injury. Eur Respir J 2003; 21:1040-1045
19. 2-mediated arachidonic acid release in intact platelets. Arch Pharm (Weinheim) 2002; 335:547-55
20. Laemmli UK: Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature 1970; 227:680-685
21. 2 synthesis. J Immunol 1997; 159:391-400
22. 2 in inflammatory diseases and trauma. Biochim Biophys Acta 2000; 1488:83-90
23. 2 isoforms: A perspective. Cell Signal 2003; 15:637-665
24. 2. J Immunol 2003; 171:995-1000
25. Baker CS, Evans TW, Randle BJ, et al: Damage to surfactant-specific protein in acute respiratory distress syndrome. Lancet 1999; 353:1232-1237
26. 2. Nat Immunol 2000; 1:42-46
27. 2 with membrane in the macrophage cell line RAW 264.7. J Biol Chem 1990; 265:5409-5413
28. 2 in alveolar type II epithelial cells: Biochemical and immunologic characterization. Am J Physiol 1993; 264(3 Pt 1):L261-L268
29. 2 and turnover of alveolar DPPC. Am J Physiol Lung Cell Mol Physiol 2001; 280:L748-L754
30. Weaver TE, Na CL, Stahlman M: Biogenesis of lamellar bodies, lysosome-related organelles involved in storage and secretion of pulmonary surfactant. Semin Cell Dev Biol 2002; 13:263-270
31. 2 activities are increased in human adult respiratory distress syndrome. Am J Physiol 1995; 269:L109-L118
32. 2, in patients with suspected sepsis and organ failure. Crit Care Med 2003; 31:718-728
33. 2 and cytokines in patients with sepsis. Res Commun Mol Pathol Pharmacol 1995; 90:413-421
34. 2 in severe sepsis: Relation to endotoxin, cytokines and thromboxane B2. Infection 1996; 24:103-118
35. 2 in patients with septic shock and trauma. Int Care Med 1994; 20:553-561
36. 2 and cachectin levels in adult respiratory distress syndrome and multiple-organ failure. Clin Biochem 1992; 25:55-60
37. Zhou W, McColum MO, Levine BA, et al: Role of platelet-activating factor in pancreatitis-associated acute lung injury in the rat. Am J Pathol 1992; 140:971-979
38. Casals C, Herrera L, Miguel E, et al: Comparison between intra- and extracellular surfactant in respiratory distress induced by oleic acid. Biochim Biophys Acta 1989; 2003:201-203
39. Deleted in proof
40. Nakos G, Kitsiouli E, Tsangaris I, et al: Bronchoalveolar lavage fluid characteristics of early intermediate and late phases of ARDS: Alterations in leukocytes, proteins, PAF and surfactant components. Intensive Care Med 1998; 24:296-303
41. Nakos G, Pneumatikos J, Tsangaris H, et al: Protein and phospholipids in BAL from patients with hydrostatic pulmonary edema. Am J Respir Crit Care Med 1997; 155:945-951
42. Triggiani M, De Marino V, Sofia M, et al: Characterization of platelet-activating factor acetylhydrolase in human bronchoalveolar lavage. Am J Respir Crit Care Med 1997; 156:94-100
43. Grisson CK, Orme JF, Richer LD, et al: Platelet-activating factor acetylhydrolase is increased in lung lavage fluid from patients with acute respiratory distress syndrome. Crit Care Med 2003; 31:770-775
44. Ohshima N, Ishii S, Izumi T, et al: Receptors-dependent metabolism of platelet-activating factor in murine macrophages. J Biol Chem 2002; 277:9722-9727
45. Luhr OR, Antonsen K, Karlsson M, et al: Incidence and mortality after acute respiratory failure and acute respiratory distress syndrome in Sweden, Denmark, and Iceland: The ARF Study Group. Am J Respir Crit Care Med 1999; 159:1849-1861
46. Roupie E, Lepage E, Wysocki M, et al: Prevalence, etiologies and outcome of the acute respiratory distress syndrome among hypoxemic ventilated patients: SRLF Collaborative Group on Mechanical Ventilation. Societe de Reanimation de Langue Francaise. Intensive Care Med 1999; 25:920-929
47. Opal S, Laterre PF, Abraham E, et al: Recombinant human platelet-activating factor acetylhydrolase for treatment of severe sepsis: Results of a phase III, multicenter, randomized, double-blind, placebo-controlled, clinical trial. The Controlled Mortality Trial of Platelet-Activating Factor Acetylhydrolase in Severe Sepsis (COMPASS) Investigators. Crit Care Med 2004;32:332-341
48. Schuster DP, Metzler M, Opal S, et al: Recombinant platelet activating factor acetylhydrolase to prevent acute respiratory distress syndrome and mortality in severe sepsis: A phase IIb, multicenter, randomized, placebo-controlled, clinical trial. Crit Care Med 2003;31:1612-1619